Silverleafe Capital Partners, LLC Arcutis Biotherapeutics, Inc. Transaction History
Silverleafe Capital Partners, LLC
- $275 Million
- Q2 2025
A detailed history of Silverleafe Capital Partners, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Silverleafe Capital Partners, LLC holds 14,500 shares of ARQT stock, worth $206,190. This represents 0.07% of its overall portfolio holdings.
Number of Shares
14,500
Previous 26,208
44.67%
Holding current value
$206,190
Previous $409,000
50.37%
% of portfolio
0.07%
Previous 0.15%
Shares
2 transactions
Others Institutions Holding ARQT
# of Institutions
252Shares Held
126MCall Options Held
605KPut Options Held
170K-
Suvretta Capital Management, LLC New York, NY11.4MShares$162 Million7.82% of portfolio
-
Jennison Associates LLC11.4MShares$162 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$156 Million4.91% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$125 Million8.65% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$123 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $856M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...